Overview

Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

Status:
Unknown status
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To assess the use of Avastin for the management of serosanguinous maculopathy
Phase:
Phase 3
Details
Lead Sponsor:
Singapore National Eye Centre
Treatments:
Bevacizumab